FDA-cleared profile

Quantib Brain

Quantib BV · MRI · FDA-cleared (510(k))

Authorized purpose: Automatic brain-structure labeling, visualization, volumetric quantification, and WMH-candidate assessment as complementary information for trained professionals evaluating MR brain images and preparing quantitative reports.

Clinical role
Automated brain segmentation and volumetric analysis with user review/editing of WMH candidates before validation and optional longitudinal comparison across exams.
Images and patients
MRI · Brain structures including grey matter, white matter, cerebrospinal fluid, intracranial volume, and white matter hyperintensity candidates
Key limitation
Keep in mind: WMH candidates must be reviewed and, if needed, edited before validation. With contrast-enhanced 3DT1w plus T2w FLAIR, absolute and relative brain-tissue volumes and relative WMH volumes are not reported; absolute WMH measures and WMH longitudinal analysis are displayed. The device is a post-processing plugin for GE Advantage Workstation AW 4.7 or AW Server AWS 3.2 with Volume Viewer Apps 13.0 Ext 4 or higher.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Automatic brain-structure labeling, visualization, volumetric quantification, and WMH-candidate assessment as complementary information for trained professionals evaluating MR brain images and preparing quantitative reports.
  • Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Brain structures including grey matter, white matter, cerebrospinal fluid, intracranial volume, and white matter hyperintensity candidates Input: A 3D T1-weighted MR image, with an additional T2-weighted FLAIR MR image for WMH segmentation; contrast-enhanced 3DT1w scans are accepted for WMH processing but do not produce all measures.
  • Who uses it?Intended users: Trained medical professionals, particularly radiology specialists
  • What does the software produce?Output: Segmentations, visualizations, and absolute/relative volumetric measurements for GM, WM, CSF, and ICV; visualization and quantification of WMH candidates; and longitudinal analysis for brain-tissue and WMH segmentations across multiple exams.
  • What is its most important limitation?Key limitation: WMH candidates must be reviewed and, if needed, edited before validation. With contrast-enhanced 3DT1w plus T2w FLAIR, absolute and relative brain-tissue volumes and relative WMH volumes are not reported; absolute WMH measures and WMH longitudinal analysis are displayed. The device is a post-processing plugin for GE Advantage Workstation AW 4.7 or AW Server AWS 3.2 with Volume Viewer Apps 13.0 Ext 4 or higher.

Clinical takeaway. Clinical role: Automatic brain-structure labeling, visualization, volumetric quantification, and WMH-candidate assessment as complementary information for trained professionals evaluating MR brain images and preparing quantitative reports.

Evidence takeaway. Evidence from the reviewed source record: FDA brain-volumetry validation compared automatic segmentations with manual segmentations on 33 3DT1w MR images across vendors and representative scan settings: Dice was 0.78 +/- 0.05 for CSF, 0.84 +/- 0.02 for GM, 0.86 +/- 0.02 for WM, and 0.97 +/- 0.00 for ICV; absolute differences in relative volumes were 1.8 +/- 1.0, 2.7 +/- 2.0, and 2.8 +/- 1.9 percentage points for CSF, GM, and WM. A WMH set of 45 3DT1w images with corresponding T2w FLAIR produced average Dice 0.61 +/- 0.13; the relative-volume difference was 0.5 +/- 0.5 percentage points over 38 non-contrast cases. These are segmentation and volume endpoints, not sensitivity or specificity.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Automatic brain-structure labeling, visualization, volumetric quantification, and WMH-candidate assessment as complementary information for trained professionals evaluating MR brain images and preparing quantitative reports.
  • Exact FDA submission
  • Checked 2026-09-09
Workflow role
Automated brain segmentation and volumetric analysis with user review/editing of WMH candidates before validation and optional longitudinal comparison across exams.
  • Exact FDA submission
  • Checked 2026-09-09
Required input
A 3D T1-weighted MR image, with an additional T2-weighted FLAIR MR image for WMH segmentation; contrast-enhanced 3DT1w scans are accepted for WMH processing but do not produce all measures.
  • Exact FDA submission
  • Checked 2026-09-09
Output and clinician action
Segmentations, visualizations, and absolute/relative volumetric measurements for GM, WM, CSF, and ICV; visualization and quantification of WMH candidates; and longitudinal analysis for brain-tissue and WMH segmentations across multiple exams.
  • Exact FDA submission
  • Checked 2026-09-09
Intended users
Trained medical professionals, particularly radiology specialists
  • Exact FDA submission
  • Checked 2026-09-09
Limitations
WMH candidates must be reviewed and, if needed, edited before validation. With contrast-enhanced 3DT1w plus T2w FLAIR, absolute and relative brain-tissue volumes and relative WMH volumes are not reported; absolute WMH measures and WMH longitudinal analysis are displayed. The device is a post-processing plugin for GE Advantage Workstation AW 4.7 or AW Server AWS 3.2 with Volume Viewer Apps 13.0 Ext 4 or higher.
  • Exact FDA submission
  • Checked 2026-09-09
Evidence summary
FDA brain-volumetry validation compared automatic segmentations with manual segmentations on 33 3DT1w MR images across vendors and representative scan settings: Dice was 0.78 +/- 0.05 for CSF, 0.84 +/- 0.02 for GM, 0.86 +/- 0.02 for WM, and 0.97 +/- 0.00 for ICV; absolute differences in relative volumes were 1.8 +/- 1.0, 2.7 +/- 2.0, and 2.8 +/- 1.9 percentage points for CSF, GM, and WM. A WMH set of 45 3DT1w images with corresponding T2w FLAIR produced average Dice 0.61 +/- 0.13; the relative-volume difference was 0.5 +/- 0.5 percentage points over 38 non-contrast cases. These are segmentation and volume endpoints, not sensitivity or specificity.
  • Exact FDA submission
  • Checked 2026-09-09

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA brain-volumetry validation compared automatic segmentations with manual segmentations on 33 3DT1w MR images across vendors and representative scan settings: Dice was 0.78 +/- 0.05 for CSF, 0.84 +/- 0.02 for GM, 0.86 +/- 0.02 for WM, and 0.97 +/- 0.00 for ICV; absolute differences in relative volumes were 1.8 +/- 1.0, 2.7 +/- 2.0, and 2.8 +/- 1.9 percentage points for CSF, GM, and WM. A WMH set of 45 3DT1w images with corresponding T2w FLAIR produced average Dice 0.61 +/- 0.13; the relative-volume difference was 0.5 +/- 0.5 percentage points over 38 non-contrast cases. These are segmentation and volume endpoints, not sensitivity or specificity.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

Quantib Brain regulatory performance study summary

  • DesignStand-Alone Performance
  • PopulationPopulation described in the exact-submission ACR model card
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K173939
  • IndependenceIndependence not established

K173939

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K173939. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-09
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: A 3D T1-weighted MR image, with an additional T2-weighted FLAIR MR image for WMH segmentation; contrast-enhanced 3DT1w scans are accepted for WMH processing but do not produce all measures.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-09 · FDA K173939: Quantib Brain

  2. Routing

    Source context, not route validation: Quantib Brain is a post-processing plugin for the GE Advantage Workstation/AW Server environment and uses the specified Volume Viewer Apps platform. The FDA packet does not establish a generic PACS, RIS, or EHR interface.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-09 · FDA K173939: Quantib Brain

  3. AI processing

    Source context, not route validation: The exact FDA package describes Quantib Brain as a post-processing plugin for the GE Advantage Workstation (AW 4.7) or AW Server (AWS 3.2) platforms, using Volume Viewer Apps 13.0 Ext 4 or higher. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "Quantib™ Brain is post-processing analysis software for the GE Advantage Workstation (AW 4.7) and AW Server (AWS 3.2) platforms using Volume Viewer Apps. 13.0 Ext 4 (or higher)." … "Quantib™ Brain is a post-processing plugin for the GE Advantage Workstation (AW 4.7) or AW Server (AWS 3.2) platforms.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA K173939: Quantib Brain

  4. Returned objects

    Source context, not route validation: Segmentations, visualizations, and absolute/relative volumetric measurements for GM, WM, CSF, and ICV; visualization and quantification of WMH candidates; and longitudinal analysis for brain-tissue and WMH segmentations across multiple exams.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-09 · FDA K173939: Quantib Brain

  5. Viewer/worklist/report

    Unresolved route: Segmentations, visualizations, and absolute/relative volumetric measurements for GM, WM, CSF, and ICV; visualization and quantification of WMH candidates; and longitudinal analysis for brain-tissue and WMH segmentations across multiple exams.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-09 · FDA K173939: Quantib Brain

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes Quantib Brain as a post-processing plugin for the GE Advantage Workstation (AW 4.7) or AW Server (AWS 3.2) platforms, using Volume Viewer Apps 13.0 Ext 4 or higher. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Quantib™ Brain is post-processing analysis software for the GE Advantage Workstation (AW 4.7) and AW Server (AWS 3.2) platforms using Volume Viewer Apps. 13.0 Ext 4 (or higher)." … "Quantib™ Brain is a post-processing plugin for the GE Advantage Workstation (AW 4.7) or AW Server (AWS 3.2) platforms.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
Quantib Brain is a post-processing plugin for the GE Advantage Workstation/AW Server environment and uses the specified Volume Viewer Apps platform. The FDA packet does not establish a generic PACS, RIS, or EHR interface.
  • Exact FDA submission
  • Checked 2026-09-09
Training
The 510(k) summary states Quantib Brain is intended to provide the trained medical professional with complementary information for the evaluation and assessment of MR brain images and to aid the trained medical professional in quantitative reporting.
  • Exact FDA submission
  • Checked 2026-10-27

User qualification wording only; the summary specifies no training program or training offering for this device.

Supported acquisition environment

Scanner manufacturers: All

exact submission · checked 2026-09-01

Confirm currently supported software versions, protocols, and site-specific acquisition configurations.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for Quantib Brain; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-09
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K173939
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
MRI
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Anatomy
Brain structures including grey matter, white matter, cerebrospinal fluid, intracranial volume, and white matter hyperintensity candidates
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2018-03-09
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
24Fields reviewed
9Source classes checked
1Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains 1 PubMed and 0 ClinicalTrials.gov candidate record. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 1 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Care setting: Not publicly available - checked 2026-11-14 - Exact FDA submission

    The exact FDA decision document was reviewed on 2026-11-14 and does not state a care setting or patient population for the subject device. Confirm intended sites and patients with the vendor and local policy.

  • Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission

    No public price or quote for the exact K173939 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-09 - Exact FDA submission

    Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.

  • Installation timeline: Not yet reviewed
  • Monitoring: Not verified - checked 2026-09-09 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

7 sources - 3 history items

Source ledger

  1. FDA K173939: Quantib Brain

    U.S. Food and Drug Administration - Published 2018-03-09 - Accessed 2026-09-09

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, deployment

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Quantib Brain model card (K173939)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, output, limitations, evidenceSummary, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K173939

    U.S. Food and Drug Administration - Accessed 2026-09-09

    Scope: postmarketSafety

Research history

  1. K173939 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K261405

ANDI 2.2

Imeka Solutions, Inc.

Authorized purpose: ANDI 2.2 processes brain MR images for atlas-assisted visualization, segmentation and volumetric quantification, presenting adjunctive DICOM-readable information for trained medical professionals; it does not predict, diagnose or interpret brain health.

Modality
MRI
Anatomy
Brain
Decision
2026-05-28
FDA-cleared K261273

Neurophet AQUA

Neurophet., Inc.

Authorized purpose: Neurophet AQUA is intended for automatic labeling, visualization, and volumetric quantification of segmentable brain structures and lesions from a set of MR images; volumetric data may be compared to reference percentile data.

Modality
MRI
Anatomy
Brain; segmentable structures and lesions
Decision
2026-05-15
FDA-cleared K260032

Morph

BeauBrain Healthcare, Inc.

Authorized purpose: Morph automatically labels, visualizes, and volumetrically quantifies segmentable brain structures from MR images and may compare measurements with reference percentile data; it is adjunctive and not the sole basis for final decisions.

Modality
MRI
Anatomy
Brain
Decision
2026-05-13
FDA-cleared K254015

CoLumbo C-Spine

Smart Soft Healthcare AD

Authorized purpose: Post-process previously acquired cervical-spine MR images to segment vertebrae and disks, calculate quantitative measurements, label out-of-range values, and export results for user review and interpretation.

Modality
MRI
Anatomy
Cervical spine: vertebrae C3-C7 and disks C2C3 through C7T1
Decision
2026-04-01

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history